Telix is a commercial-stage biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic (‘theranostic’) radiopharmaceuticals. Telix’s extensive pipeline for urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning is ...

"Telix is now a global radiopharmaceutical company with a specialist commercial organization, a deep pipeline of late-stage and next-generation theranostic programs, and global manufacturing capabilities. We are further differentiated by our end-to-end solutions for patients and our fully integrated radiopharma ecosystem." Read more

2025年2月20日 · Telix today announces its financial results for the year ended 31 December 2024. All figures are in AU$ unless stated otherwise. Total revenue, driven primarily from sales of Illuccix® of $783.2 million, up by 56% 1 from $502.5 million in 2023, beating full year guidance 2.

Telix Pharmaceuticals的研发管线旨在解决前列腺癌、肾癌（肾癌）、脑癌（ 胶质母细胞瘤 ）和血液系统癌症（骨髓调节）以及一系列免疫和罕见疾病中未满足的重大医疗需求。 01 前列腺癌

Telix is a commercial-stage biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic (‘theranostic’) radiopharmaceuticals. Telix’s extensive pipeline for urologic oncology, neuro-oncology, musculoskeletal oncology and hematology is underpinned by a strong global supply, manufacturing and ...

2025年2月20日 · Grow precision medicine: Prepared for launch of three new products TLX007-CDx (Gozellix®), TLX101-CDx (Pixclara®) and TLX250-CDx (Zircaix®)4 in 2025 while continuing to increase sales and market share for Illuccix®.Deliver late-stage therapeutics: Expanded ProstACT GLOBAL Phase 3 prostate cancer therapy trial recruitment in the U.S. and continue...

2 天之前 · The latest Telix Pharmaceuticals Limited [TLX] news, articles, data and analysis from The Australian Financial Review

Historical price to book ratio values for Telix Pharmaceuticals (TLX) over the last 10 years.

6 天之前 · Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States.

2025年3月14日 · Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to …